Brii Biosciences Limited

OTCPK:BRIB.F Stock Report

Market Cap: US$137.4m

Brii Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:BRIB.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Jan 25BuyUS$4,413Zhi HongIndividual34,250US$0.13
03 Jan 25BuyUS$9,193Zhi HongIndividual73,000US$0.13
02 Jan 25BuyUS$9,313Zhi HongIndividual72,500US$0.13
31 Dec 24BuyUS$8,075Zhi HongIndividual62,500US$0.13
27 Dec 24BuyUS$9,137Zhi HongIndividual71,000US$0.13
13 Dec 24BuyUS$5,772Zhi HongIndividual50,000US$0.12
12 Dec 24BuyUS$17,665Zhi HongIndividual151,500US$0.12
11 Dec 24BuyUS$2,596Zhi HongIndividual21,500US$0.12
25 Nov 24BuyUS$2,636Zhi HongIndividual20,500US$0.13
22 Nov 24BuyUS$3,727Zhi HongIndividual28,500US$0.13
21 Nov 24BuyUS$2,408Zhi HongIndividual18,000US$0.13
25 Sep 24BuyUS$5,285Zhi HongIndividual39,000US$0.14
24 Sep 24BuyUS$9,594Zhi HongIndividual71,000US$0.14
24 Sep 24SellUS$6,664Ankang LiIndividual49,500US$0.13
23 Sep 24BuyUS$7,595Zhi HongIndividual58,000US$0.13
20 Sep 24BuyUS$5,176Zhi HongIndividual41,500US$0.12
26 Aug 24SellUS$187Ankang LiIndividual1,500US$0.12

Insider Trading Volume

Insider Buying: BRIB.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BRIB.F?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders34,900,6474.77%
Institutions115,452,48615.8%
VC/PE Firms162,430,03022.2%
General Public418,202,10957.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 24 shareholders own 42.79% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.4%
Arch Venture Partners, L.P.
90,410,418US$17.0m0%1.44%
9.85%
Boyu Capital Group Management Ltd.
72,019,612US$13.5m0%1.29%
4.62%
Invesco Ltd.
33,751,238US$6.3m0%no data
4.5%
Zhi Hong
32,891,690US$6.2m1.13%no data
4.1%
Yunfeng Capital
29,995,664US$5.6m0%1.6%
2.65%
E Fund Management Co., Ltd.
19,357,110US$3.6m0%no data
2.28%
JPMorgan Chase & Co, Brokerage and Securities Investments
16,642,038US$3.1m0%no data
0.83%
Reorient Group Limited, Asset Management Arm
6,073,846US$1.1m0%19.8%
0.8%
Zhonggeng Fund Management Co., Ltd.
5,878,500US$1.1m0%0.02%
0.29%
JP Morgan Asset Management
2,099,000US$394.6k0%no data
0.2%
Ankang Li
1,442,957US$271.3k17.7%no data
0.11%
GF Fund Management Co., Ltd.
800,000US$150.4k-88.5%no data
0.056%
Dimensional Fund Advisors LP
406,791US$76.5k-37%no data
0.036%
State Street Global Advisors, Inc.
261,000US$49.1k0%no data
0.03%
Taiyin Yang
218,000US$41.0k100%no data
0.015%
American Century Investment Management Inc
112,000US$21.1k0%no data
0.012%
Yiu Wa Tsui
87,000US$16.4k19.2%no data
0.012%
Gregg Alton
87,000US$16.4k19.2%no data
0.012%
Martin J. Murphy
87,000US$16.4k19.2%no data
0.012%
Hui Tang
87,000US$16.4k19.2%no data
0.0083%
Hwabao WP Fund Management Co., Ltd
60,500US$11.4k0%no data
0.0019%
UBS Asset Management AG
14,000US$2.6k-99.7%no data
0.00007%
Purekind Fund Management Co.,Ltd.
500US$96.20%no data
0.00004%
Norges Bank Investment Management
299US$55.0-0.33%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/05 13:57
End of Day Share Price 2024/07/08 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Brii Biosciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangbin ZhouChina International Capital Corporation Limited
Xiao Wei LinEverbright Securities Co. Ltd.
Geoffrey PorgesLeerink Partners LLC